메뉴 건너뛰기




Volumn 97, Issue 5, 2007, Pages 866-868

Any effect of CYP2C9 variants on warfarin clearance in Chinese patients? [1]

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; MENADIONE EPOXIDE; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOSIDE REDUCTASE COMPLEX 1; WARFARIN;

EID: 34249093270     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-04-0195     Document Type: Letter
Times cited : (3)

References (17)
  • 1
    • 4544288090 scopus 로고    scopus 로고
    • Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose
    • Zhao F, Loke C, Rankin SC, et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 2004; 76:210-219.
    • (2004) Clin Pharmacol Ther , vol.76 , pp. 210-219
    • Zhao, F.1    Loke, C.2    Rankin, S.C.3
  • 2
    • 24944503322 scopus 로고    scopus 로고
    • A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity
    • Yuan HY, Chen JJ, Lee MTM, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-1751.
    • (2005) Hum Mol Genet , vol.14 , pp. 1745-1751
    • Yuan, H.Y.1    Chen, J.J.2    Lee, M.T.M.3
  • 3
    • 33646479231 scopus 로고    scopus 로고
    • CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese
    • Chern HD, Ueng TH, Fu YP, et al. CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese. Clin Chim Acta 2006; 367: 108-113.
    • (2006) Clin Chim Acta , vol.367 , pp. 108-113
    • Chern, H.D.1    Ueng, T.H.2    Fu, Y.P.3
  • 4
    • 18244400400 scopus 로고    scopus 로고
    • Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?
    • You JHS, Chan FWH, Wong RSM, et al. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 2005; 59: 582-587.
    • (2005) Br J Clin Pharmacol , vol.59 , pp. 582-587
    • You, J.H.S.1    Chan, F.W.H.2    Wong, R.S.M.3
  • 5
    • 0022997648 scopus 로고
    • Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship
    • Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet 1986; 11: 483-504.
    • (1986) Clin Pharmacokinet , vol.11 , pp. 483-504
    • Holford, N.H.G.1
  • 6
    • 0028149598 scopus 로고
    • Stereochemical aspects of warfarin drug interactions. Use of a combined pharmacokinetic-pharmacodynamic model
    • Chan E, McLachlan A, O'Reilly R, et al. Stereochemical aspects of warfarin drug interactions. Use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther 1994; 56: 286-294.
    • (1994) Clin Pharmacol Ther , vol.56 , pp. 286-294
    • Chan, E.1    McLachlan, A.2    O'Reilly, R.3
  • 7
    • 0036085787 scopus 로고    scopus 로고
    • Genetic polymorphisms in assessing interindividual variability in delivered dose
    • Haber LT, Maier A, Gentry PR, et al. Genetic polymorphisms in assessing interindividual variability in delivered dose. Reg Toxicol Pharmacol 2002; 35: 177-197.
    • (2002) Reg Toxicol Pharmacol , vol.35 , pp. 177-197
    • Haber, L.T.1    Maier, A.2    Gentry, P.R.3
  • 8
    • 25144502325 scopus 로고    scopus 로고
    • Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population
    • Veenstra DL, You JHS, Rieder MJ, et al. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 2005; 15: 687-691.
    • (2005) Pharmacogenet Genomics , vol.15 , pp. 687-691
    • Veenstra, D.L.1    You, J.H.S.2    Rieder, M.J.3
  • 9
    • 0035078166 scopus 로고    scopus 로고
    • Development and validation of a sensitive and robust LC-tandem MS method for the analysis of warfarin enantiomers in human plasma
    • Naidong W, Ring PR, Midtlien C, et al. Development and validation of a sensitive and robust LC-tandem MS method for the analysis of warfarin enantiomers in human plasma. J Pharm Biomed Anal 2001; 25: 219-226.
    • (2001) J Pharm Biomed Anal , vol.25 , pp. 219-226
    • Naidong, W.1    Ring, P.R.2    Midtlien, C.3
  • 10
    • 0031807762 scopus 로고    scopus 로고
    • Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes
    • Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63: 519-528.
    • (1998) Clin Pharmacol Ther , vol.63 , pp. 519-528
    • Takahashi, H.1    Kashima, T.2    Nomizo, Y.3
  • 11
    • 0037374422 scopus 로고    scopus 로고
    • Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients
    • Takahashi H, Wilkinson G, Caraco Y, et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003; 73: 253-263.
    • (2003) Clin Pharmacol Ther , vol.73 , pp. 253-263
    • Takahashi, H.1    Wilkinson, G.2    Caraco, Y.3
  • 12
    • 1842526962 scopus 로고    scopus 로고
    • 5′-Flanking region polymorphisms of CYP2C9 and their relationship, to S-warfarin metabolism in white and Japanese patients
    • Takahashi H, Ieiri I, Wilkinson GR, et al. 5′-Flanking region polymorphisms of CYP2C9 and their relationship, to S-warfarin metabolism in white and Japanese patients. Blood 2004; 103: 3055-3057.
    • (2004) Blood , vol.103 , pp. 3055-3057
    • Takahashi, H.1    Ieiri, I.2    Wilkinson, G.R.3
  • 13
    • 31344451857 scopus 로고    scopus 로고
    • Different contributions of polymorphism in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
    • Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphism in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16: 10 1-110.
    • (2006) Pharmacogenet Genomics , vol.16 , Issue.10 , pp. 1-110
    • Takahashi, H.1    Wilkinson, G.R.2    Nutescu, E.A.3
  • 14
    • 23044440450 scopus 로고    scopus 로고
    • The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirement: Proposal for a new dosing regimen
    • Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirement: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
    • (2005) Blood , vol.106 , pp. 2329-2333
    • Sconce, E.A.1    Khan, T.I.2    Wynne, H.A.3
  • 15
    • 1542346414 scopus 로고    scopus 로고
    • Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin
    • Kamali F, Khan TI, King BP, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 2004; 75: 204-212.
    • (2004) Clin Pharmacol Ther , vol.75 , pp. 204-212
    • Kamali, F.1    Khan, T.I.2    King, B.P.3
  • 16
    • 0029123928 scopus 로고
    • The influence of age, liver size and enantiomer concentrations on warfarin requirements
    • Wynne H, Cope L, Kelly P, et al. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Pharmacol 1995; 40: 203-207.
    • (1995) Br J Pharmacol , vol.40 , pp. 203-207
    • Wynne, H.1    Cope, L.2    Kelly, P.3
  • 17
    • 0036914221 scopus 로고    scopus 로고
    • Influence of CYP2C9 and CYP2C19 genetic polymorphism on warfarin maintenance dose and metabolic clearance
    • Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphism on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72: 702-710.
    • (2002) Clin Pharmacol Ther , vol.72 , pp. 702-710
    • Scordo, M.G.1    Pengo, V.2    Spina, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.